ענת כהן-דייג

All engines describe Anat Cohen-Dayag as the long-time CEO of Compugen, now its Executive Chair, who moved it from computational biology services to cancer immunotherapy drug development.

Google AI Mode

Anat Cohen-Dayag served 15 years as CEO of Compugen, moved to Executive Chair, and built partnerships with AstraZeneca, Bayer, Bristol Myers Squibb and Gilead.

Copilot

Anat Cohen-Dayag led Compugen as CEO from 2010 to 2025, turning it into a clinical-stage immuno-oncology company, and is now Executive Chair.

ChatGPT

Anat Cohen-Dayag is Compugen's Executive Chair, having been its CEO from 2010 to September 2025, and led its shift into drug discovery and development.

Gemini

Anat Cohen-Dayag is a biotechnology executive known for transforming Compugen into a clinical-stage cancer immunotherapy company driven by computational biology.

4 מתוך 4 מנועי AI מזהים אותו, נמדד ב-16 באוק׳ 2026. התיאורים נוצרים על ידי מערכות AI ועלולים להיות שגויים.